Wikipedia

Intraepithelial lymphocyte

Intraepithelial lymphocytes (IEL) are lymphocytes found in the epithelial layer of mammalian mucosal linings, such as the gastrointestinal (GI) tract and reproductive tract.[1] However, unlike other T cells, IELs do not need priming. Upon encountering antigens, they immediately release cytokines and cause killing of infected _target cells. In the GI tract, they are components of gut-associated lymphoid tissue (GALT).[2]

Intestinal IELs are long-lived resistant effector cells spread along the entire length of intestine, where they patrol the space between intestinal epithelial cells (IEC) and the basement membrane (the intraepithelial space). Epithelium of small intestine contains approximately 1 IEL per 10 enterocytes.[3] Due to their constant exposure to of antigens at mucosal barrier, they have unique antigen-experienced activated phenotypes and they constantly express CD103 (αE integrin), that is distinct from the conventional T cells in the intestine.[3] IELs are mainly T cells with mixture of subsets. They are divided into two groups – conventional and unconventional IELs.[4]

In mice both groups are retained in almost equal proportions.[5] In humans, the majority of IELs are alpha beta T cells. 15% of IELs are gamma delta T cells and thus represent a minor component of human IELs. However, IELs significantly increase under certain conditions, such as celiac disease.[1]

primary biliary cirrhosis. Bile duct intraepithelial lymphocytes

Phenotype

edit

The majority of IELs (80%) are CD3+, and over 75% of these also express CD8. IELs can be divided into two major subsets based on their CD8 coreceptor expression.[5] One subset of IELs typically express activation marker CD8αα and some IELs express CD8αβ+ marker (CD8αβ promotes TCR activation, whereas CD8αα suppresses TCR signals).

In both humans and mice IELs express higher levels of CD103, activation marker CD69, granzyme B and perforin cytolytic granules. CD25 expression is lower in comparison with effector memory T cells.[6][7]

CD8αα

edit

Expression of CD8αα is an important phenotypic marker of IELs, but not all IELs subpopulations express this molecule. CD8αα homodimer is an alternative isoform to classical CD8αβ heterodimer, which is expressed on conventional CD8 T-cells. CD8αα is mainly expressed by effector or mature antigen-experienced cells in the gut. This molecule can bind MHC I, but, opposed to the function of CD8αβ, CD8αα reduces sensitivity of TCR towards antigens. Thus, when recognizing MHC I, CD8αα functions as a repressor of activation.[8]

CD8αα can also recognize thymus leukemia (TL) antigen, which is a non-classical MHC I molecule that is expressed in thymus and in intestinal epithelium. Interaction between TL and CD8αα does not serve for migration of IELs into the epithelium, but it is important for modulating immune response of IELs.[9] It has been suggested that cross-talk between TL and CD8αα might regulate IELs survival and proliferation.[8] More accurately, TL prevents proliferation of IELs, when there is co-occurrence of weak TCR stimulation.[9]

Development

edit

Induced IELs (TCRαβ+ CD8αβ+) are generated from naive T cells during an immune response. TCRαβ+ CD8αα (natural IELs) cells differentiate in the thymus.[6][10]

Development and cytolytic activation are independent of live micro-organisms but they become cytolytic in response to the exogenous antigenic substances other than live micro-organisms in the gut. IEL T cells acquire their activated memory phenotype post-thymically, in response to antigens encountered in the periphery.[11]

Function

edit

Their role in immune system is crucial because IELs provide a first line of defense at this extensive barrier with the outside world. All IEL T cells are antigen-experienced T cells, which typically display a cytotoxic functional phenotype. IELs mediate antigen-specific delayed-type hypersensitivity (DTH) responses, exhibit virus-specific CTL function, to express natural killer (NK)-like activity and produce a local graft-versus-host reaction (GVHR) when transferred to semiallogeneic hosts. IELs are also able to produce a variety of cytokines which are characteristically produced by Th1- and Th2-type cells and can also provide help for B cell responses.[6][10][11]

Pathology

edit

An elevated IEL population, as determined by biopsy, typically indicates ongoing inflammation within the mucosa. In diseases such as celiac sprue, IEL elevation throughout the small intestine is one of many specific markers.[1] IELs have heightened activated status that can lead to inflammatory disease such as IBD, promote cancer development and progression,[12] or become the malignant cells in enteropathy-associated T-cell lymphoma, a lymphoma that is a complication of celiac sprue.[13][14]

Alternatively, elevated IEL populations can be a marker for developing neoplasia in the tissue such as found in cervical and prostate cancers, as well as some colorectal cancers, particularly those associated with Lynch syndrome (hereditary non-polyposis colon cancer <HNPCC>).[15] IELs themselves can, when chronically activated, undergo mutation that can lead to lymphoma.[16]

Classification

edit

IELs can be divided into different subpopulations based on molecular markers expression, mainly by expression of TCR and CD8αα, and by origin.

Induced TCR+ IELs

edit

Also termed conventional IELs, express TCRαβ together with CD4 or CD8αβ and are derived from antigen-experienced T cells that home to intraepithelial space. Contrary to natural IELs, induced IELs are the progeny of MHCI-restricted CD8αβ or MHCII-restricted CD4 naïve T cells that further undergo a post-thymic differentiation. These cells express activation markers (CD44, CD69) and unlike natural TCR+IELs express CD2, CD5, CD28, LFA-1, and Thy1. Upon the entry into the intestinal epithelium, these cells can start express also CD8αα.[4][3]

TCRαβ+CD4+ IELs

edit

TCRαβ+CD4+ IELs arise from conventional peripheral CD4+ T-cells. These cells migrate into the intestinal epithelium as effector or tissue-resident memory T cells.

In mice, up to 50% of these IELs can express CD8αα homodimer, which they acquire in the intestinal epithelium after external stimuli such as TGF-β, IFN-γ, IL-27 and retinoic acid. Function of TCRαβ+ CD4+ CD8αα+ IELs is unclear. Even though they express granzymes and have cytolytic properties, it has been suggested that they can also have regulatory properties in the context of chronic intestinal inflammation.[3][17]

TCRαβ+CD8αβ+ IELs

edit

These IELs emerge from peripherally activated conventional CD8+ T-cells and home to the intestinal epithelium, where they function as effector or memory cells. They continuously express integrin β7, granzyme B, CD103 and CD69 and produce lower amounts of TNF-α and IFN-γ as opposed to the conventional CD8+ T-cells.[4]

Some of these cells also express CD8αα homodimer and can be pathogenic during coeliac disease in humans.[3]

Double positive (DP) TCRαβ+CD4+CD8αα+ IELs

edit

These DP IELs are subset of induced IELs, which are CD4+ IELs with some functions of CD8+ IELs and under physiological condition their number in the intestine is very small. During the intestinal inflammation, levels of DP IELs significantly increase.[18]

DP IELs develop independently of the thymus and contrary to natural IELs, these cells increase with age, especially when they are exposed to exogenous antigens. Their migration into the intestinal epithelium depends mainly on the luminal bacteria and the dietary antigens.[18]

DP IELs induction is directed by the transcriptional regulation. During the development of IELs, CD4+ T cells downregulate ThPOK and instead start to express Runx3 transcription factor, because CD4+CD8aa+ IELs have low levels of ThPOK expression while the expression of Runx3 is very high. T-bet inducing environment is also required for the Runx3 upregulation, most likely containing IFN-y, IL-27, IL-15 and Retionic acid (RA).[19] RA have the ability to induce an expression of the intetsine-homing receptors, such as α4β7-integrin and CC-chemokine receptor 9 (CCR9).[20] Another transcription factor responsible for DP IELs induction is the Aryl hydrocarbon receptor (AhR). AhR is ligand-dependent transcription factor, and its activation is responsible for ThPOK downregulation. AhR is activated by indole metabolites of tryptophan induced by microbiota, such as Lactobacillus reuteri.[21] Therefore, the DP IELs induction is dependent on the microbiota composition and the diet.

The function of CD4CD8aa IELs is due to their CD8 phenotype and granzyme B expression to prevent pathogens from invading and to maintain integrity of the intestinal epithelial barrier. Their CD4 phenotype is responsible for IL-10 and TGF-β secretion that prevents Th1-induced inflammation in the intestine, therefore their role can be complementary to T regulatory cells.[18][22]

DP IELs probably play role in intestinal homeostasis because of their immunosuppressive function. But for their cytotoxic responses they may play an important role in the pathological process of IBD.[18]

Natural TCR+ IELs

edit

Also termed unconventional IELs, express either TCRαβ or TCRγδ and do not express either CD4 or CD8αβ, but express CD8αα homodimers. In contrast to induced TCR+ IELs lack expression of CD2, CD5, CD28, LFA-1, and Thy1.[4]

TCRαβ+ IELs

edit

In mice, these IELs are the most abundant at birth and with age their numbers decrease. In humans, these cells are present during gestation but are very rare in adulthood. TCRαβ+ IELs develop in thymus where they undergo agonist positive selection and thereby are self-reactive. Nevertheless, they have regulatory properties and protect against colitis in animal experiments. These cells are influenced by normal intestinal microbiota and vitamin D. NOD2 receptor expressed by antigen presenting cells and epithelial cells in the intestine recognizes microbes and triggers the production of IL-15 cytokine, which promotes TCRαβ+CD8αα+ IELs.[3]

TCRγδ+ IELs

edit

TCRγδ+ IELs develop outside of thymus and their maintenance and function in the intestinal epithelium is influenced by a cross-talk with enterocytes. Moreover, they can migrate through the epithelium with the help of interactions with epithelial cells.[23] Most of these cells express Vγ7 in mice and Vγ4 in humans. Their function resides in the protection of the intestinal barrier against pathogens early in the infection and later they quench the inflammation and protect the barrier from tissue damage. The mechanism is not clear, but TCRγδ+ IELs have cytotoxic properties and can produce cytokines TGF-β, TNF-α, IFN-γ, IL-13 and IL-10 and antimicrobial peptides, all of which can contribute to the diverse functions.[3]

Similar functions have been found in the context of colitis, where these cells seem to have pathogenic role at the beginning, whereas later they protect the epithelium against tissue damage.[17]

TCR− IELs

edit

IELs that do not express TCR.

ILC-like IELs

edit

These cells show properties of NK cells. In humans, they are elevated during Crohn´s disease and in mice, they are pathogenic during colitis.[4]

iCD8α

edit

These innate lymphocytes express homodimer CD8αα and CD3 and develop outside of thymus. They have cytotoxic and phagocytic properties, express MHC II and thereby can present antigens to conventional CD4+ T-cells. iCD8α protect against bacterial infections and promotes experimental colitis.[3]

TCR−iCD3+CD8αα− IELs

edit

These cells are very similar to iCD8α population and it is unclear if this is a different subset of cells or only precursors of iCD8α.[3]

See also

edit

IEL of the GI tract

References

edit
  1. ^ a b c Hopper AD, Hurlstone DP, Leeds JS, McAlindon ME, Dube AK, Stephenson TJ, Sanders DS (November 2006). "The occurrence of terminal ileal histological abnormalities in patients with coeliac disease". Digestive and Liver Disease. 38 (11): 815–819. doi:10.1016/j.dld.2006.04.003. PMID 16787773.
  2. ^ DeFranco AL, Locksley RM, Robertson M (2007). The Immune Response in Infection and Inflammatory Disease. London: New Science Press. pp. 218–219. ISBN 978-0-19-920614-8.
  3. ^ a b c d e f g h i Olivares-Villagómez D, Van Kaer L (April 2018). "Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier". Trends in Immunology. 39 (4): 264–275. doi:10.1016/j.it.2017.11.003. PMC 8056148. PMID 29221933.
  4. ^ a b c d e McDonald BD, Jabri B, Bendelac A (August 2018). "Diverse developmental pathways of intestinal intraepithelial lymphocytes". Nature Reviews. Immunology. 18 (8): 514–525. doi:10.1038/s41577-018-0013-7. PMC 6063796. PMID 29717233.
  5. ^ a b Sheridan BS, Lefrançois L (December 2010). "Intraepithelial lymphocytes: to serve and protect". Current Gastroenterology Reports. 12 (6): 513–521. doi:10.1007/s11894-010-0148-6. PMC 3224371. PMID 20890736.
  6. ^ a b c Mayassi T, Jabri B (September 2018). "Human intraepithelial lymphocytes". Mucosal Immunology. 11 (5): 1281–1289. doi:10.1038/s41385-018-0016-5. PMC 6178824. PMID 29674648.
  7. ^ Lambolez F, Mayans S, Cheroutre H (2013). "Lymphocytes: Intraepithelial". eLS. American Cancer Society. doi:10.1002/9780470015902.a0001197.pub3. ISBN 9780470015902.
  8. ^ a b Cheroutre H, Lambolez F (February 2008). "Doubting the TCR coreceptor function of CD8alphaalpha". Immunity. 28 (2): 149–159. doi:10.1016/j.immuni.2008.01.005. PMID 18275828.
  9. ^ a b Olivares-Villagómez D, Van Kaer L (November 2010). "TL and CD8αα: Enigmatic partners in mucosal immunity". Immunology Letters. 134 (1): 1–6. doi:10.1016/j.imlet.2010.09.004. PMC 2967663. PMID 20850477.
  10. ^ a b Sim GK (1995-01-01). Intraepithelial lymphocytes and the immune system. Advances in Immunology. Vol. 58. pp. 297–343. doi:10.1016/s0065-2776(08)60622-7. ISBN 9780120224586. PMID 7741030.
  11. ^ a b McGhee JR (1998-01-01). "Mucosa-Associated Lymphoid Tissue (MALT)". In Delves PJ (ed.). Encyclopedia of Immunology (Second ed.). Elsevier. pp. 1774–1780. doi:10.1006/rwei.1999.0448. ISBN 9780122267659.
  12. ^ Cheroutre H (2015-01-01). "Chapter 35 - Intraepithelial TCRαβ T Cells in Health and Disease". In Mestecky J, Lefrancois L, Strober W, Russell MW, Kelsall BL (eds.). Mucosal Immunology (Fourth ed.). Academic Press. pp. 733–748. doi:10.1016/b978-0-12-415847-4.00035-5. ISBN 9780124158474.
  13. ^ Ondrejka S, Jagadeesh D (December 2016). "Enteropathy-Associated T-Cell Lymphoma". Current Hematologic Malignancy Reports. 11 (6): 504–513. doi:10.1007/s11899-016-0357-7. PMID 27900603. S2CID 13329863.
  14. ^ Chander U, Leeman-Neill RJ, Bhagat G (August 2018). "Pathogenesis of Enteropathy-Associated T Cell Lymphoma". Current Hematologic Malignancy Reports. 13 (4): 308–317. doi:10.1007/s11899-018-0459-5. PMID 29943210. S2CID 49430640.
  15. ^ Bellizzi AM, Frankel WL (November 2009). "Colorectal cancer due to deficiency in DNA mismatch repair function: a review". Advances in Anatomic Pathology. 16 (6): 405–417. doi:10.1097/PAP.0b013e3181bb6bdc. PMID 19851131. S2CID 25600795.
  16. ^ Meresse B, Malamut G, Cerf-Bensussan N (June 2012). "Celiac disease: an immunological jigsaw". Immunity. 36 (6): 907–919. doi:10.1016/j.immuni.2012.06.006. PMID 22749351.
  17. ^ a b Ma H, Qiu Y, Yang H (February 2021). "Intestinal intraepithelial lymphocytes: Maintainers of intestinal immune tolerance and regulators of intestinal immunity". Journal of Leukocyte Biology. 109 (2): 339–347. doi:10.1002/JLB.3RU0220-111. PMC 7891415. PMID 32678936.
  18. ^ a b c d Park Y, Moon SJ, Lee SW (January 2016). "Lineage re-commitment of CD4CD8αα intraepithelial lymphocytes in the gut". BMB Reports. 49 (1): 11–17. doi:10.5483/BMBRep.2016.49.1.242. PMC 4914207. PMID 26592937.
  19. ^ Reis BS, Hoytema van Konijnenburg DP, Grivennikov SI, Mucida D (August 2014). "Transcription factor T-bet regulates intraepithelial lymphocyte functional maturation". Immunity. 41 (2): 244–256. doi:10.1016/j.immuni.2014.06.017. PMC 4287410. PMID 25148025.
  20. ^ Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY (October 2004). "Retinoic acid imprints gut-homing specificity on T cells". Immunity. 21 (4): 527–538. doi:10.1016/j.immuni.2004.08.011. PMID 15485630.
  21. ^ Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, et al. (August 2017). "Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells". Science. 357 (6353): 806–810. doi:10.1126/science.aah5825. PMC 5687812. PMID 28775213.
  22. ^ Sujino T, London M, Hoytema van Konijnenburg DP, Rendon T, Buch T, Silva HM, et al. (June 2016). "Tissue adaptation of regulatory and intraepithelial CD4⁺ T cells controls gut inflammation". Science. 352 (6293): 1581–1586. Bibcode:2016Sci...352.1581S. doi:10.1126/science.aaf3892. PMC 4968079. PMID 27256884.
  23. ^ Hoytema van Konijnenburg DP, Reis BS, Pedicord VA, Farache J, Victora GD, Mucida D (November 2017). "Intestinal Epithelial and Intraepithelial T Cell Crosstalk Mediates a Dynamic Response to Infection". Cell. 171 (4): 783–794.e13. doi:10.1016/j.cell.2017.08.046. PMC 5670000. PMID 28942917.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Intraepithelial_lymphocyte&oldid=1194515948"
  NODES
Note 1